IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.266
AS - Asia 13.989
EU - Europa 10.655
SA - Sud America 1.866
Continente sconosciuto - Info sul continente non disponibili 634
AF - Africa 380
OC - Oceania 40
Totale 48.830
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.422
CN - Cina 7.006
SG - Singapore 2.902
IE - Irlanda 2.218
HK - Hong Kong 1.697
UA - Ucraina 1.573
BR - Brasile 1.372
FI - Finlandia 1.177
DE - Germania 1.142
IT - Italia 1.136
VN - Vietnam 1.092
RU - Federazione Russa 934
SE - Svezia 754
FR - Francia 692
GB - Regno Unito 553
CA - Canada 353
IN - India 266
BD - Bangladesh 184
AR - Argentina 176
ZA - Sudafrica 135
MX - Messico 126
IQ - Iraq 98
PK - Pakistan 87
NL - Olanda 82
JP - Giappone 79
TR - Turchia 79
CO - Colombia 74
PL - Polonia 63
CR - Costa Rica 61
ID - Indonesia 60
EC - Ecuador 59
ES - Italia 57
VE - Venezuela 56
SA - Arabia Saudita 53
UZ - Uzbekistan 48
AT - Austria 46
JM - Giamaica 41
MA - Marocco 40
CL - Cile 39
GT - Guatemala 37
BE - Belgio 36
IL - Israele 36
NI - Nicaragua 36
AU - Australia 34
HN - Honduras 33
KE - Kenya 32
PH - Filippine 31
TT - Trinidad e Tobago 30
CW - ???statistics.table.value.countryCode.CW??? 29
IR - Iran 29
PR - Porto Rico 29
MY - Malesia 28
SV - El Salvador 28
CZ - Repubblica Ceca 27
TN - Tunisia 26
JO - Giordania 25
PY - Paraguay 25
EG - Egitto 24
BO - Bolivia 23
LT - Lituania 22
AE - Emirati Arabi Uniti 20
EU - Europa 20
MU - Mauritius 20
PA - Panama 19
NP - Nepal 18
PE - Perù 18
ET - Etiopia 17
UY - Uruguay 17
AZ - Azerbaigian 16
DK - Danimarca 16
DZ - Algeria 16
EE - Estonia 16
GP - Guadalupe 16
KR - Corea 16
SC - Seychelles 16
RO - Romania 15
LB - Libano 13
KZ - Kazakistan 12
PT - Portogallo 12
SN - Senegal 11
OM - Oman 10
RS - Serbia 10
AL - Albania 9
BG - Bulgaria 9
DO - Repubblica Dominicana 9
PS - Palestinian Territory 9
XK - ???statistics.table.value.countryCode.XK??? 9
CH - Svizzera 8
KW - Kuwait 8
LV - Lettonia 8
NG - Nigeria 8
AM - Armenia 7
BH - Bahrain 7
KG - Kirghizistan 7
MD - Moldavia 7
SK - Slovacchia (Repubblica Slovacca) 7
GR - Grecia 6
SY - Repubblica araba siriana 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
Totale 48.131
Salva come PNG Salva come JPEG
Città #
Chandler 2.220
Dublin 2.210
Jacksonville 2.004
San Jose 1.979
Hong Kong 1.650
Nanjing 1.557
Ashburn 1.546
Singapore 1.437
Dallas 1.250
Council Bluffs 1.242
Beijing 871
Boardman 789
Nanchang 615
Princeton 516
Lauterbourg 506
Lawrence 495
Wilmington 494
Hebei 462
Shenyang 456
Los Angeles 436
Changsha 412
Ho Chi Minh City 398
Jiaxing 372
Medford 350
New York 280
Helsinki 257
Hangzhou 249
Hanoi 239
Tianjin 238
Santa Clara 216
Buffalo 215
Ann Arbor 206
Milan 187
Redondo Beach 150
Munich 134
Moscow 133
Shanghai 133
Woodbridge 114
São Paulo 110
Toronto 106
Norwalk 99
Rome 94
Orem 91
Brooklyn 85
Seattle 84
Chicago 83
Johannesburg 82
Verona 78
Pavia 73
The Dalles 71
Houston 68
Tokyo 68
Montreal 67
Nuremberg 67
San Francisco 66
Frankfurt am Main 62
Turku 62
Jinan 61
Atlanta 60
Da Nang 58
Haiphong 56
Washington 55
Falls Church 54
Guangzhou 54
Chennai 52
Warsaw 52
San José 49
Zhengzhou 49
Falkenstein 48
Columbus 47
Mexico City 47
Naples 47
Fairfield 43
London 42
Tashkent 42
Kunming 41
Baghdad 40
Des Moines 40
Stockholm 39
Denver 38
North Bergen 38
Phoenix 38
Ningbo 37
Rio de Janeiro 36
Belo Horizonte 35
Managua 35
Boston 34
Brussels 34
Taizhou 31
Manchester 30
Charlotte 29
Hải Dương 29
Willemstad 29
Nairobi 28
Brasília 26
Curitiba 26
Florence 24
Guatemala City 24
Guayaquil 24
Amsterdam 23
Totale 30.258
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 201
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 195
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data 185
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 184
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 182
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. 181
A B-cell lymphoproliferative disorder 180
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 168
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 160
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 160
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 160
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 159
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 158
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 157
Blast phase of essential thrombocythemia: A single center study. 156
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 156
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 155
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 154
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 153
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 152
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 152
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 152
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 152
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 150
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 150
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 149
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 148
A case of persistent eosinophilia 146
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 146
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 146
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 145
[Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons] 144
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 142
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 142
Anemia associata ad endocrinopatie. 142
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 142
A gain-of-function mutation of JAK2 in myeloproliferative disorders 142
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 140
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 140
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 139
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. 139
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 138
Classification and prognostic evaluation of myelodysplastic syndromes 138
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 138
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 135
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 135
Cell cycle distribution of cord blood-derived haematopoietic progenitor cells and their recruitment into the S-phase of the cell cycle 134
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 132
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 132
A chronic lymphoproliferative disorder 131
"In vitro" megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura. 131
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 130
A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndrome. 129
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 129
Ittero. 128
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 128
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 128
Juvenile chronic myelogenous leukemia: in vitro characterization before and after allogeneic bone marrow transplantation 128
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 127
Clinical significance of somatic mutation in unexplained blood cytopenia 127
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 126
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 126
Revised international prognostic scoring system for myelodysplastic syndromes 126
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 125
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 125
Translational pathophysiology: a novel molecular mechanism of human disease 124
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q 124
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 124
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 122
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 122
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 122
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. 122
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 122
Pan-cancer analysis of whole genomes 122
Hematologic passport for athletes competing in endurance sports: a feasibility study. 121
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 121
Somatic mutations of calreticulin in myeloproliferative neoplasms 121
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 120
Cerebrospinal fluid ferritin in human disease. 120
Allelic imbalance in CALR somatic mutagenesis 120
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 120
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 120
Clinical and biological implications of driver mutations in myelodysplastic syndromes 120
A patient-oriented approach to treatment of myelodysplastic syndromes. 120
JAK2 (V617F) mutation in healthy individuals 119
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. 119
Relationship between clone metrics and clinical outcome in clonal cytopenia 118
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 118
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 118
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 118
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 117
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 117
Natural history of juvenile haemochromatosis 116
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 116
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 116
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 116
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 116
Myelodysplastic syndromes--coping with ineffective hematopoiesis. 116
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. 116
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. 116
Totale 13.709
Salva come PNG Salva come JPEG
Categoria #
all - tutte 214.594
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 214.594
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.044 0 0 0 0 101 130 40 119 120 93 340 1.101
2022/20236.356 743 374 47 520 634 706 3 403 2.629 33 164 100
2023/20242.266 253 446 95 204 219 618 65 137 15 53 60 101
2024/20255.893 156 567 173 188 109 216 239 540 1.230 224 677 1.574
2025/202614.965 1.044 1.234 1.656 1.792 1.504 761 3.040 594 1.224 1.174 573 369
2026/20274.741 332 957 1.101 2.213 138 0 0 0 0 0 0 0
Totale 48.830